Formosa signs deal with Cristália to commercialise APP13007 in Brazil
APP13007 is designed to teat inflammation and pain post-ocular surgery and is undergoing evaluation by the US Food…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
29 Jan 24
APP13007 is designed to teat inflammation and pain post-ocular surgery and is undergoing evaluation by the US Food…
25 Jan 24
The multi-year collaboration allows GSK to leverage Elegen’s cell-free synthetic DNA production technology, in exchange for up to…
25 Jan 24
The integrated business will now serve those with severe diseases, including those caused by genetics, where there is…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
25 Jan 24
Derived from the company’s WuXia cell line platform, WuXia ADCC PLUS is a superior-performing and high-yielding mammalian cell…
25 Jan 24
Under this new partnership, VGXI will serve as a trusted plasmid DNA manufacturer to support Resilience's advanced therapy…
25 Jan 24
New developments in the biopharmaceutical field fuel a need for highly scalable and flexible solutions
24 Jan 24
Inhibrx shareholders will receive $30 per share in cash, a CVR that can be exchanged for $5, plus…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
24 Jan 24
Obese participants, who were administered with up to 30mg oral ecnoglutide once-daily for six weeks, achieved a mean…
24 Jan 24
OpCT-001 is the lead cell therapy candidate being developed under the strategic R&D agreement that was formed in…
24 Jan 24
Under the partnership, both entities will use GenEdit's NanoGalaxy platform to explore and advance innovative nanoparticles, facilitating the…